Výsledky vyhledávání - "Aino Telaranta-Keerie"

SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC)

Autor: Toni K. Choueiri, Wanning Xu, Lynne Poole, Aino Telaranta-Keerie, Ryan Hartmaier, Thomas Powles

Publikováno v: Journal of Clinical Oncology. 40:TPS4601-TPS4601

TPS4601 Background: Papillary renal cell carcinoma (PRCC) is the most common subtype of non-clear cell RCC and accounts for 10–15% of RCCs. Approximately 80% of PRCC cases are MET-driven, characterized by genomic abnormalities resulting in dysregul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84c536e3fe5c78733db5c689098b77e7
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4601

Zobrazit plný text záznamu

Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib

Autor: Juliann Chmielecki, Yi-Long Wu, Ji-Youn Han, Jhanelle E. Gray, Yuri Rukazenkov, Carin R. Espenschied, X. Huang, Alexander Kohlmann, Rachel Hodge, Justin I. Odegaard, Suresh Ramalingam, J. Carl Barrett, Aino Telaranta-Keerie

Publikováno v: Journal of Clinical Oncology. 38:9553-9553

9553 Background: Genotyping is required to identify cancer patients (pts) eligible for targeted therapy; however, many do not receive biomarker testing, in part due to limitations associated with tissue-only genotyping practices and the growing list

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e49c0fa4799e7f62ca2c87c648daa883
https://doi.org/10.1200/jco.2020.38.15_suppl.9553

Zobrazit plný text záznamu

Company Profile: Lab21 Ltd

Autor: Aino Telaranta-Keerie, Berwyn Clarke

Publikováno v: Pharmacogenomics. 13:1453-1457

Pharmacogenetics is essential in the discovery of individual differences in metabolism and response to drugs, as well as in increasing the understanding of disease mechanisms. In addition, the use of biomarker assays is now critical in personalized m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f6e91d48dd911bb2a0f6fbb5b5d3aa75
https://doi.org/10.2217/pgs.12.135

Zobrazit plný text záznamu

Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints

Autor: Matti Härkönen, Ritva Kara, Pentti Sipponen, Aino Telaranta-Keerie, Lea Paloheimo

Publikováno v: Scandinavian journal of gastroenterology. 45(9)

The objective of this observational study was to estimate the prevalence of advanced atrophic corpus gastritis (ACG) among Finnish adult volunteers without specific complaints using a biomarker blood test. The objective also was to assess the feasibi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::556cd53988fda0268da1e96a5812a9de
https://pubmed.ncbi.nlm.nih.gov/20446846

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání